Diagnosis of portal hypertensive gastropathy

Current Opinion in Gastroenterology

Volumn 19, Issue 5, 2003, Pages 477-482

  Burak, Kelly W ^a,b   Beck, Paul L ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b Gastrointestinal Research Group   (Canada)

Author keywords

Congestive gastropathy; Endoscopy; Gastric antral vascular ectasia syndrome; Varices

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ISOSORBIDE MONONITRATE; NADOLOL; OCTREOTIDE; OMEPRAZOLE; PROPRANOLOL; SOMATOSTATIN; TERLIPRESSIN; VASOPRESSIN;

BLEEDING; DISEASE SEVERITY; GASTROSCOPY; HUMAN; INCIDENCE; LIVER TRANSPLANTATION; PATHOGENESIS; PORTAL HYPERTENSION; PORTAL HYPERTENSIVE GASTROPATHY; PORTOSYSTEMIC ANASTOMOSIS; REVIEW; SCORING SYSTEM; STOMACH DISEASE;

EID: 0042887502     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200309000-00008     Document Type: Review

References (62)

1. Primignani M, Carpinelli L, Preatoni P, et al.: Natural history of portal hypertensive gastropathy in patients with liver cirrhosis. The New italian Endoscopic Club for the study and treatment of esophageal varices (NIEC). Gastroenterology 2000, 119:181-187. A large recent study assessing the natural history of PHG. The prevalence of PHG was 80%. PHG was stable in 29%, deteriorated in 23%, improved in 23%, and fluctuated with time in 25%. Acute bleeding from gastropathy occurred in 8 of 315 patients (2.5%). The bleeding-related mortality rate was 12.5%. Chronic bleeding occurred in 34 patients (10.8%).
2. Sarin SK, Sreenivas DV, Lahoti D, et al.: Factors influencing development of portal hypertensive gastropathy in patients with portal hypertension. Gastroenterology 1992, 102:994-999 [see comments].
3. Gupta R, Sawant P, Parameshwar RV, et al.: Gastric mucosal blood flow and hepatic perfusion index in patients with portal hypertensive gastropathy. J Gastroenterol Hepatol 1998, 13:921-926.
4. Sacchetti C, Capello M, Rebecchi P, et al.: Frequency of upper gastrointestinal lesions in patients with liver cirrhosis. Dig Dis Sci 1988, 33:1218-1222.
5. Iwao T, Toyonaga A, Oho K, et al.: Portal-hypertensive gastropathy develops less in patients with cirrhosis and fundal varices. J Hepatol 1997, 26:1235-1241.
6. Bayraktar Y, Balkanci F, Uzunalimoglu B, et al.: Is portal hypertension due to liver cirrhosis a major factor in the development of portal hypertensive gastropathy? Am J Gastroenterol 1996, 91:554-558. This study examined the relation between PHG in patients with PH due to cirrhosis, noncirrhotic patients with extrahepatic portal vein obstruction, cirrhotic patients with extrahepatic and 57 control subjects. Snakeskin, scarlatina rash, diffuse hyperemia, and diffuse bleeding were frequent endoscopic gastric findings in cirrhotic patients. These findings were seen less frequently in noncirrhotic patients with portal hypertension caused by portal vein obstruction than in cirrhotic patients (P<0.0001). The highest incidence was seen in cirrhotic patients with portal vein obstruction (P<0.001). Positive correlations existed among the endoscopic findings, the clinical estimate of the cirrhosis severity (Child-Pugh grade), and the size and appearance of esophageal varices.
7. Parikh SS, Desai SB, Prabhu SR, et al.: Congestive gastropathy: factors influencing development, endoscopic features, Helicobacter pylori infection, and microvessel changes. Am J Gastroenterol 1994, 89:1036-1042.
8. Taranto D, Suozzo R, Romano M, et al.: et al. Gastric endoscopic features in patients with liver cirrhosis: correlation with esophageal varices, intra-variceal pressure, and liver dysfunction. Digestion 1994, 55:115-120.
9. McCormack TT, Sims J, Eyre-Brook I, et al.: Gastric lesions in portal hypertension: inflammatory gastritis or congestive gastropathy? Gut 1985, 26:1226-1232. This is excellent study was the first to propose a standardized system for grading PHG. The authors' proposed scoring system is likely the most commonly used system in the present literature. They assessed the incidence and natural history of PHG in a series of 127 patients with PH of various causes. Gastritis was observed endoscopically in 65 patients (51%) and was of two main types. Twenty-eight patients had severe or persistent gastritis, which caused clinically significant bleeding on 80 occasions and accounted for 25% of the bleeds from all sources.
10. Cales P, Zabotto B, Meskens C, et al.: Gastroesophageal endoscopic features in cirrhosis: observer variability, interassociations, and relationship to hepatic dysfunction. Gastroenterology 1990, 98:156-162.
11. Zaman A, Hapke R, Flora K, et al.: Prevalence of upper and lower gastrointestinal tract findings in liver transplant candidates undergoing screening endoscopic evaluation. Am J Gastroenterol 1999, 94:895-899 [see comments]. The authors showed a high incidence of PHG in patients being assessed for liver transplantation: 73% of patients had esophageal varices, 62% PHG, and 16% gastric had varices. Excluding varices and PHG, endoscopic findings in the upper gastrointestinal tract (n = 120) included 13% esophagitis/ulcers, 7.5% gastritis, 8% duodenitis, 2% Barrett esophagus, 3% duodenal ulcers, and 2% gastric ulcers. Findings in the lower gastrointestinal tract (n = 71) included 21% adenomatous polyps, 7% rectal varices, and 3% colopathy.
12. Gupta R, Saraswat VA, Kumar M, et al.: Frequency and factors influencing portal hypertensive gastropathy and duodenopathy in cirrhotic portal hypertension. J Gastroenterol Hepatol 1996, 11:728-733.
13. Kamath PS, Lacerda M, Ahlquist DA, et al.: Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis. Gastroenterology 2000, 118:905-911. Assessed portal pressure and response to TIPS in a group of patients with PHG and GAVE. 75% with severe PHG responded to TIPS, 89% of patients with mild PHG had endoscopic resolution. Patients with GAVE had neither endoscopic resolution nor a decrease in transfusion requirements after TIPS.
14. Sarin SK, Misra SP, Singal A, et al.: Evaluation of the incidence and significance of the "mosaic pattern" in patients with cirrhosis, noncirrhotic portal fibrosis, and extrahepatic obstruction. Am J Gastroenterol 1988, 83:1235-1239.
15. Sarin SK, Shahi HM, Jain M, et al.: The natural history of portal hypertensive gastropathy: influence of variceal eradication. Am J Gastroenterol 2000, 95:2888-2893. Specifically assessed the impact of variceal eradication on PHG. The authors found that PHG developing after variceal eradication is often transitory and less severe. Variceal eradication can worsen preexisting PHG.
16. Amarapurkar DN, Dhawan PS, Chopra K, et al.: Stomach in portal hypertension. J Assoc Physicians India 1993, 41:638-640.
17. Rabinovitz M, Yoo YK, Schade RR, et al.: Prevalence of endoscopic findings in 510 consecutive individuals with cirrhosis evaluated prospectively. Dig Dis Sci 1990, 35:705-710.
18. Chaves DM, Sakai P, Mucenic M, et al.: Comparative study of portal hypertensive gastropathy in schistosomiasis and hepatic cirrhosis. Endoscopy 2002, 34:199-202.
19. Kotzampassi K, Eleftheriadis E, Aletras H: The "mosaic-like" pattern of portal hypertensive gastric mucosa after variceal eradication by sclerotherapy. J Gastroenterol Hepatol 1990, 5:659-663.
20. de la Pena J, Rivero M, Sanchez E, et al.: Variceal ligation compared with endoscopic sclerotherapy for variceal hemorrhage: prospective randomized trial. Gastrointest Endosc 1999, 49:417-423. The authors found that variceal ligation was superior to sclerotherapy in terms of the rate of recurrent bleeding but worse with respect to recurrence of varices and the evolution of portal hypertensive gastropathy.
21. Sarin SK, Govil A, Jain AK, et al.: Prospective randomized trial of endoscopic sclerotherapy versus variceal band ligation for esophageal varices: influence on gaetropathy, gastric varicee and variceal recurrence. J Hepatol 1997, 26:826-832.
22. Hou MC, Lin HC, Chen CH, et al.: Changes in portal hypertensive gastropathy after endoscopic variceal sclerotherapy or ligation: an endoscopic observation. Gastrointest Endosc 1995, 42:139-144.
23. Pereira-Lima JC, Zanette M, Lopes CV, de Mattos AA: The influence of endoscopic variceal ligation on the portal pressure gradient in cirrhotics. Hepatogastroenterology 2003, 50:102-106.
24. Panes J, Bordas JM, Pique JM, et al.: Increased gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. Gastroenterology 1992, 103:1875-1882 [see comments]. This study and the three that follow assessed the effects of various agents on gastric blood flow in patients with cirrhosis, greatly adding to our understanding of the pathophysiology underlying PHG.
25. Panes J, Bordas JM, Pique JM, et al.: Effects of propranolol on gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. Hepatology 1993, 17:213-218. See [24••].
26. Panes J, Pique JM, Bordas JM, et al.: Reduction of gastric hyperemia by glypressin and vasopressin administration in cirrhotic patients with portal hypertensive gastropathy. Hepatology 1994, 19:55-60. See [24••].
27. Panes J, Pique JM, Bordas JM, et al.: Effect of bolus injection and continuous infusion of somatostatin on gastric perfusion in cirrhotic patients with portal-hypertensive gastropathy. Hepatology 1994, 20:336-341. See [24••].
28. Panes J, Casadevall M, Fernandez M, et al.: Gastric microcirculatory changes of portal-hypertensive rats can be attenuated by long-term estrogen-progestagen treatment. Hepatology 1994, 20:1261-1270.
29. Ohta M, Hashizume M, Higashi H, et al.: Portal and gastric mucosal hemodynamics in cirrhotic patients with portal-hypertensive gastropathy. Hepatology 1994, 20:1432-1436 [see comments].
30. Beck PL, Lee SS, McKnight GW, Wallace JL: Characterization of spontaneous and ethanol-induced gastric damage in cirrhotic rats. Gastroenterology 1992, 103:1048-1055.
31. Payen JL, Cales P, Pienkowski P, et al.: Weakness of mucosal barrier in portal hypertensive gastropathy of alcoholic cirrhosis: effects of propranolol and enprostil. J Hepatol 1995, 23:689-696.
32. Iwao T, Toyonaga A, Ikegami M, et al.: Reduced gastric mucosal blood flow in patients with portal-hypertensive gastropathy. Hepatology 1993, 18:36-40.
33. Yoshikawa I, Murata I, Nakano S, Otsuki M: Effects of endoscopic variceal ligation on portal hypertensive gaetropathy and gastric mucosal blood flow. Am J Gastroenterol 1998, 93:71-74.
34. Piasecki C, Chin J, Greenslade L, et al.: Endoscopic detection of ischaemia with a new probe indicates low oxygenation of gastric epithelium in portal hypertensive gastropathy. Gut 1995, 36:654-656.
35. Iwao T, Toyonaga A, Sumino M, et al.: Portal hypertensive gastropathy in patients with cirrhosis. Gastroenterology 1992, 102:2060-2065.
36. Bahnacy A, Kupcsulik P, Eles ZS, et al.: Helicobacter pylori and congestive gastropathy. Z Gastroenterol 1997, 35:109-112. The conclusion was that this organism does not affect the development of PHG.
37. Dai L, Wu X: Chung Hua Kan Tsang Ping Tsa Chih 1999, 7:22-23. [Helicobacter pylori and congestive gastropathy] See [36•].
38. Balan KK, Jones AT, Roberts NB, et al.: The effects of Helicobacter pylori colonization on gastric function and the incidence of portal hypertensive gastropathy in patients with cirrhosis of the liver. Am J Gastroenterol 1996, 1:1400-1406 [see comments]. See [36•].
39. Munoz J, Albillos A, Perez-Paramo M, et al.: Factors mediating the hemodynamic effects of tumor necrosis factor-alpha in portal hypertensive rats. Am J Physiol 1999, 276:G687-693.
40. Burak KW, Lee SS, Beck PL: Portal hypertensive gastropathy and gastric antral vascular ectasia (GAVE) syndrome. Gut 2001,49:866-672. A detailed review of the epidemiology, pathogenesis and treatment of PHG.
41. Ohta M, Pai R, Kawanaka H, et al.: Expression of endothelin-1, and endothelin A and B receptors in portal hypertensive esophagus of rats. J Physiol Pharmacol 2000, 51:57-67.
42. Wang JY, Hsieh JS, Huang TJ: The effect of portal hypertension on transforming growth factor-alpha and epidermal growth factor receptor in the gastric mucosa of rats. Int Surg 1996, 83:220-223.
43. Toyonaga A, Iwao T: Portal-hypertensive gastropathy. J Gastroenterol Hepatol 1998, 13:865-877.
44. Carpinelli L, Primignani M, Preatoni P, et al.: Portal hypertensive gastropathy: reproducibility of a classification, prevalence of elementary lesions, sensitivity and specificity in the diagnosis of cirrhosis of the liver: a NIEC multicentre study. New Italian Endoscopic Club. Ital J Gastroenterol Hepatol 1997, 29:533-540 [see comments]. An important paper on the formulation of the NIEC grading system for PHG.
45. Spina GP, Arcidiacono R, Bosch J, et al.: Gastric endoscopic features in portal hypertension: final report of a consensus conference, Milan, Italy, September 19, 1992. J Hepatol 1994, 21:461-467. A report from a consensus conference that further details the approach to grading PHG.
46. Yoo HY, Eustace JA, Verma S, et al.: Accuracy and reliability of the endoscopic classification of portal hypertensive gastropathy. Gastrointest Endosc 2002, 56:675-680. This study directly assesses the accuracy and reproducibility of a 2CCS and a 3CCS in grading PHG.
47. Tanoue K, Hashizume M, Wada H, et al.: Effects of endoscopic injection sclerotherapy on portal hypertensive gastropathy: a prospective study. Gastrointest Endosc 1992, 38:582-585. This study was the first to propose a 3CCS for grading PHG.
48. de Franchis R: Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 2000, 33:846-852. A report on a consensus conference on assessing and treating several conditions associated with PHG.
49. Payen JL, Cales P, Voigt JJ, et al.: Severe portal hypertensive gastropathy and antral vascular ectasia are distinct entities in patients with cirrhosis. Gastroenterology 1995, 108:138-144 [see comments]. A very important paper that differentiates PHG from GAVE syndrome. A must-read for most endoscopists as well as others who are involved in treating or diagnosing PHG or GAVE.
50. Merkel C, Marin R, Sacerdoti D, et al.: Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000, 31:324-329.
51. Perez-Ayuso RM, Pique JM, Bosch J, et al.: Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet 1991, 337:1431-1434 [see comments]. An important small study that assesses the role of propranolol in the management of PHG.
52. Lo GH, Lai KH, Cheng JS, et al.: The effects of endoscopic variceal ligation and propranolol on portal hypertensive gastropathy: a prospective, controlled trial. Gastrointest Endosc 2001, 53:579-584.
53. Kouroumalis EA, Koutroubakis IE, Manousos ON: Somatostatin for acute severe bleeding from portal hypertensive gastropathy. Eur J Gastroenterol Hepatol 1998, 10:509-512. A good small study that examines the benefits of somatostatin in the treatment of PHG. An initial injection of 250 μg bolus somatostatin, followed by a continuous infusion of 250 μg/h for 3 days (100 μg and 50 μg/h for octreotide), arrested bleeding in all 26 patients, and in 23 there was no hospital relapse.
54. Zhou Y, Qiao L, Wu J, et al.: Comparison of the efficacy of octreotide, vasopressin, and omeprazole in the control of acute bleeding in patients with portal hypertensive gastropathy: a controlled study. J Gastroenterol Hepatol 2002, 17:973-979. An important study that assesses the role of various agents in the treatment of PHG.
55. Bruha R, Marecek Z, Spicak J, et al.: Double-blind randomized, comparative multicenter study of the effect of terlipressin in the treatment of acute esophageal variceal and/or hypertensive gastropathy bleeding. Hepatogastroenterology 2002, 49:1161-1166. This study clearly shows that terlipressin may be another therapeutic agent in the treatment of patients with bleeding from PHG and varices.
56. Orloff MJ, Orloff MS, Orloff SL, Haynes KS: Treatment of bleeding from portal hypertensive gastropathy by portacaval shunt. Hepatology 1995, 21:1011-1017 [see comments].
57. Soin AS, Acharya SK, Mathur M, et al.: Portal hypertensive gastropathy in noncirrhotic patients: the effect of lienorenal shunts. J Clin Gastroenterol 1998, 26:64-67; discussion 68.
58. Urata J, Yamashita Y, Tsuchigame T, et al.: The effects of transjugular intrahepatic portosystemic shunt on portal hypertensive gastropathy. J Gastroenterol Hepatol 1998, 13:1061-1067 [see comments].
59. Sezai S, Ito M, Sakurai Y, et al.: Effects on gastric circulation of treatment for portal hypertension in cirrhosis. Dig Dis Sci 1998, 43:1302-1306.
60. McCormick PA, Sankey EA, Cardin F, et al.: Congestive gastropathy and Helicobacter pylori: an endoscopic and morphometric study. Gut 1991, 32:351-354.
61. D'Amico G, Montalbano L, Traina M, et al.: Natural history of congestive gastropathy in cirrhosis. The Liver Study Group of V. Cervello Hospital. Gastroenterology 1990, 99:1558-1564. A good earlier study examining the natural history of PHG.
62. DeWeert TM, Gostout CJ, Wiesner RH: Congestive gastropathy and other upper endoscopic findings in 81 consecutive patients undergoing orthotopic liver transplantation. Am J Gastroenterol 1990, 85:573-576. An earlier study that examined the upper gastrointestinal tract findings in patients undergoing liver transplantation; this study is complemented by [11•].